The University of Oxford has announced plans to establish a new Poonawalla Vaccines Research building with a funding commitment of GBP 50 million from India’s Serum Life Sciences. Serum Life Sciences is wholly-owned by the Poonawalla family, owners of the Adar Poonawalla-led Serum Institute of India, and the proposed research facility will focus on vaccinology, the university said on Wednesday.
The facility will be established at the university’s Old Road Campus, and will house over 300 research scientists. It is expected to provide the focus and scale for the university’s major vaccine development programmes allowing a rapid, productive and timely expansion of this fast-growing translational area.
Read|SII Executive Director Suresh Jadhav Dies; Adar Poonawalla, Soumya Swaminathan Mourn Death
“I am delighted that through this generous gift, we will be able to further our work on vaccines which have proven so critical to global health. We will also ensure that we are never again caught unprepared for a global pandemic,” Professor Louise Richardson, vice-chancellor of the University of Oxford. “The university has longstanding ties with the Poonawalla family and we were delighted to confer an honorary degree on Cyrus Poonawalla in Summer 2019 in recognition of his extraordinary work manufacturing inexpensive vaccines for the developing world,” she said.
The Poonawalla building will house the headquarters and main laboratory space of the Jenner Institute, the world-leading academic vaccine institute named after Edward Jenner, the father of vaccination.
Read|With No Orders from Govt, SII to Cut Covishield Production by 50%: Adar Poonawalla
The most recent serum institute-Jenner Institute collaboration saw the rapid development and global roll-out of the Oxford-AstraZeneca COVID-19 vaccine at scale, manufactured and administered in India as Covishield. Further, Serum Institute and Jenner Institute collaborations include an agreement for Serum Institute to manufacture and develop, with large scale supply, the Jenner Institute’s new R21/Matrix-M malaria vaccine, currently in Phase III trials, prioritising countries with high malaria burdens.
The university said the donation reinforces and builds on the Serum Institute of India’s long-standing partnership with Oxford University. “Vaccines save lives, and the development of vaccines has been the lifelong focus of the Poonawalla family. We are committed to developing and supplying vaccines to people who need them most,” said Natasha Poonawalla, Executive Director, Serum Institute of India.
Read all the Latest News, Breaking News and Coronavirus News here.
( News Source :Except for the headline, this story has not been edited by Rashtra News staff and is published from a www.news18.com feed.)
Related searches :
